AcelRx Pharmaceuticals (ACRX) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a hold rating to a buy rating in a report published on Tuesday. The brokerage currently has $2.50 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

ACRX has been the subject of several other research reports. ValuEngine lowered shares of AcelRx Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, October 12th. HC Wainwright reiterated a buy rating and set a $10.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, October 3rd. Piper Jaffray Companies reiterated a hold rating and set a $2.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, October 13th. Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the company a buy rating in a research note on Thursday, October 12th. Finally, Jefferies Group lowered shares of AcelRx Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $6.21.

AcelRx Pharmaceuticals (ACRX) traded down $0.02 on Tuesday, reaching $2.03. 195,000 shares of the company traded hands, compared to its average volume of 413,950. The firm has a market capitalization of $101.94, a PE ratio of -1.81 and a beta of 2.96. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a 1 year low of $1.55 and a 1 year high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). sell-side analysts predict that AcelRx Pharmaceuticals will post -1.06 earnings per share for the current year.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards bought 30,000 shares of the stock in a transaction on Tuesday, November 14th. The stock was purchased at an average price of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the director now directly owns 150,000 shares in the company, valued at $285,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.10% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Perennial Advisors LLC bought a new position in shares of AcelRx Pharmaceuticals during the third quarter worth about $138,000. Geller Family Office Services LLC bought a new position in shares of AcelRx Pharmaceuticals during the third quarter worth about $460,000. Virtu KCG Holdings LLC grew its position in shares of AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of AcelRx Pharmaceuticals during the second quarter worth about $530,000. Institutional investors and hedge funds own 13.70% of the company’s stock.

WARNING: This report was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.truebluetribune.com/2018/01/19/acelrx-pharmaceuticals-acrx-lifted-to-buy-at-zacks-investment-research.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply